Development pipeline

Indatuximab Ravtansine (BT-062)

Indatuximab Ravtansine (BT-062) is an immune conjugate, consisting of a monoclonal antibody to which a highly effective cytotoxic maytansien derivative (DM4) is coupled. The immune conjugate technology, developed by ImmunoGen, Inc, is used for toxin conjugation. The antibody is directed against the CD138 receptor, which is over-expressed on multiple myeloma cells and on other cells of various types of cancer: solid tumors.

After the conjugate is absorbed into the target cell, DM4 is released and exerts its cytotoxic activity so that the tumor cell is killed. This combination of high effectiveness and specificity with low systemic toxicity distinguishes BT-062 from most therapies currently used in oncology.

Press releases

ImmunoGen has elected not to exercise its late stage co...

24.03.2017, News

ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) - License agreement with ImmunoGen will continue ... [More]

Encouraging data of Indatuximab Ravtansine (BT-062) in ...

06.12.2016, News

Encouraging data of Indatuximab Ravtansine (BT-062) in combination therapy in advanced Multiple Myeloma - New data from BT-062 in combination therapy presented at 58th annual conference of ... [More]

Biotest increases revenues in first half year 2015 by 8...

11.08.2015, News

Biotest increases revenues in first half year 2015 by 8.9% - Clinical development of BT-061 will be discontinued - Capacity expansion at headquarter Dreieich on schedule - Board of ... [More]

Encouraging Efficacy of Indatuximab Ravtansine (BT-062)...

09.12.2014, News

Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone - New data from combination therapy study presented at 56th ... [More]

Further preclinical studies emphasise the potential of ...

24.10.2014, News

Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours - Antibody-drug conjugate shows high efficacy in an animal model in the treatment of ... [More]

Biotest continues to show a sales increase

07.05.2014, News

Biotest continues to show a sales increase - Sales at EUR 122.2 million (+2.9%) - Progress in CapEx program "Biotest Next Level" - Positive development in R&D projects Dreieich,7 May ... [More]

Biotest AG initiates clinical study with Indatuximab Ra...

27.03.2014, News

Biotest AG initiates clinical study with Indatuximab Ravtansine (BT-062) in solid tumors - First patient treated in phase I/IIa study (no. 989) in patients with triple-negative metastatic ... [More]

Clinical Study with Indatuximab Ravtansine (BT-062) in ...

10.12.2013, News

Clinical Study with Indatuximab Ravtansine (BT-062) in Multiple Myeloma shows good Tolerability and encouraging Efficacy in Combination with Lenalidomide and Dexamethasone - Efficacy and ... [More]

Biotest Group with double digit EBIT growth

13.08.2012, News

Biotest Group with double digit EBIT growth - Sales increase to EUR 220.2 mio. - EBIT increase by 14.5% to EUR 22.9 EUR mio. - Management confirms guidance 2012 Dreieich, 13 August 2012. ... [More]

Biotest AG starts combination therapy study with BT-06...

16.07.2012, News

Biotest AG starts combination therapy study with BT-062 in multiple myeloma - Antibody-drug conjugate BT-062 continues to show good tolerability in monotherapy - First patient treated in ... [More]

Biotest Group reports substantially higher EBIT

10.05.2012, News

Biotest Group reports substantially higher EBIT - EBIT up 14.3% at EUR 10.4 million - Sales increased to EUR 107.7 million - Management Board confirms forecast Dreieich, 10 May 2012. The ... [More]

Biotest reached an all-time high Profit after Tax

22.03.2012, News

Biotest reached an all-time high Profit after Tax - Profit after tax of the Biotest Group (Continuing Operations and Discontinued Operation) at EUR48.1 million represents an increase of ... [More]

BT-062 demonstrates rapid and complete tumor eradicatio...

22.03.2012, News

BT-062 demonstrates rapid and complete tumor eradication in preclinical studies - Pronounced anti-tumor activity against aggressive solid tumors, e.g. human breast, pancreas, bladder and ... [More]

Clinical development of BT-062 in multiple myeloma expa...

12.12.2011, News

Clinical development of BT-062 in multiple myeloma expands into combination therapy  Efficacy and tolerability data from monotherapy studies 969 and 975 presented at 53rd annual conference of ... [More]

Biotest: Significant Increase in Profit after Tax

10.11.2011, News

Biotest: Significant Increase in Profit after Tax - Increase of Profit after tax by 31.1% (Continuing and Discontinued Operations) - Profit after tax contribution of EUR 22 million from sale ... [More]

Sales increase despite difficult market environment

22.03.2011, News

Sales increase despite difficult market environment  Sales increased by 5.7% to EUR 412.5 million, EBIT decreased by 24.9% due to a difficult market environment for plasma proteins  Biotest ... [More]

Clinical and pre-clinical data emphasise the potential ...

06.12.2010, News

Clinical and pre-clinical data emphasise the potential of BT-062 in multiple myeloma  Phase I clinical trial: BT-062 leads to clinical benefit in more than 50 % of patients with continued ... [More]

Biotest: Pre-clinical studies demonstrate high efficacy...

17.11.2010, News

Biotest: Pre-clinical studies demonstrate high efficacy of BT-062 in solid tumours  Immunoconjugate induces complete remission of human solid tumours in mouse models  High anti-tumour ... [More]

Biotest experiences sales growth

08.11.2010, News

Biotest experiences sales growth  Sales after nine months 3.5% above the previous year  Performance continues to be affected by the difficult market environment  Board of Management ... [More]

Positive perspective despite difficult environment

12.08.2010, News

Positive perspective despite difficult environment - Final results for first half of 2010: sales increased by 4 % - Earnings situation burdened by market environment - Important progress in R&D ... [More]

Conference dates

03.12.2016 – 06.12.2016 | San Diego

Publications

preview

ASH 2014 American Society of Hematology (06.12.2014 – 09.12.2014, San Francisco)
PDF, 398.98 kB
[ Download ]

preview

World ADC Weltkongress Antibody Drug Conjugates (26.10.2014 – 29.10.2014, San Diego)
PDF, 834.64 kB
[ Download ]

preview

ASH 2013 American Society of Hematology (06.12.2013 - 10.12.2013, New Orleans)
PDF, 41.61 kB
[ Download ]

preview

ASH 2012 American Society of Hematology, 8. - 11. Dez. 2012, Atlanta (USA)
PDF, 387.58 kB
[ Download ]

preview

Tassone et al.: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 1;104(12):3688-96
[ Link ]

preview

Ikeda et al.: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009, Jun 15;15(12):4028-37
[ Link ]

Clinical trials

Title

Indication

Status

 
Indatuximab Ravtansine (Study 983) Multiple myeloma Study ongoing

BT062 in Combination With Lenalidomide/Dexamethasone in Patients With Multiple Myeloma

Link clinicaltrials.gov
 
Indatuximab Ravtansine (Study 975) Multiple myeloma Study completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine (Study 969) Multiple myeloma Study completed

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

 
Indatuximab Ravtansine* (Study 989) Solid tumors Study ongoing

An open-label, twostage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder

Link clinicaltrialsregister.eu